US 12,391,751 B2
Antibody against advanced glycation end products and use thereof
Tetsuro Yamamoto, Kumamoto (JP); Shota Tsuchida, Kumamoto (JP); Tomoaki Shigeta, Kumamoto (JP); Kazumi Sasamoto, Kumamoto (JP); and Mami Chirifu, Kumamoto (JP)
Assigned to BLOOM TECHNOLOGY CORPORATION, Kumamoto (JP)
Filed by Bloom Technology Corporation, Kumamoto (JP)
Filed on Apr. 29, 2024, as Appl. No. 18/648,976.
Application 18/648,976 is a division of application No. 17/271,381, granted, now 12,006,358, previously published as PCT/JP2019/034195, filed on Aug. 30, 2019.
Claims priority of application No. 2018-163668 (JP), filed on Aug. 31, 2018; and application No. 2018-248166 (JP), filed on Dec. 28, 2018.
Prior Publication US 2024/0301045 A1, Sep. 12, 2024
Int. Cl. C07K 16/18 (2006.01); C07D 241/12 (2006.01)
CPC C07K 16/18 (2013.01) [C07D 241/12 (2013.01); C07K 2317/92 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A monoclonal antibody or antigen binding fragment thereof, wherein:
the monoclonal antibody has complementarity determining regions in a heavy-chain variable region (VH CDR1, VH CDR2, and VH CDR3) and a light-chain variable region (VL CDR1, VL CDR2, and VL CDR3) that comprise:
(1-1)
(a) VH CDR1: the amino acid sequence of SEQ ID NO 1;
(b) VH CDR2: the amino acid sequence of SEQ ID NO 2;
(c) VH CDR3: the amino acid sequence of SEQ ID NO 3;
(d) VL CDR1: the amino acid sequence of SEQ ID NO 5;
(e) VL CDR2: the amino acid sequence of SEQ ID NO 6; and
(f) VL CDR3: the amino acid sequence of SEQ ID NO 7; or
(1-2)
(g) VH CDR1: the amino acid sequence of SEQ ID NO 15;
(h) VH CDR2: the amino acid sequence of SEQ ID NO 16;
(i) VH CDR3: the amino acid sequence of SEQ ID NO 17;
(j) VL CDR1: the amino acid sequence of SEQ ID NO 19;
(k) VL CDR2: the amino acid sequence of SEQ ID NO 20; and
(1) VL CDR3: the amino acid sequence of SEQ ID NO 21; and
the monoclonal antibody or the antigen binding fragment thereof is capable of binding to a compound represented by formula (XI) or (XII):

OG Complex Work Unit Chemistry
wherein R1, R2, R3 and R4 are each independently selected from a hydrogen atom, and a protecting group,
Q1 represents a hydrogen atom or a group —CH2-X1—Y1;
Q2 represents a hydrogen atom or a group —CH2-X2—Y2; X1 and X2 represent —O— or —NH—;
Y1 and Y2 represent a hydrogen atom, a protecting group, or a group:

OG Complex Work Unit Chemistry
R5 and R6 are each independently selected from a hydrogen atom, and a protecting group; or a cationic radical thereof, or a dication thereof.